Annual Drug Patent Expirations for RYALTRIS
Ryaltris is a drug marketed by Glenmark Specialty and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug.
This drug has sixty-five patent family members in twenty-eight countries.
The generic ingredient in RYALTRIS is mometasone furoate; olopatadine hydrochloride. One supplier is listed for this compound. Additional details are available on the mometasone furoate; olopatadine hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
